The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia Challenge, 2012Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia
Objective/Rationale:
Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky movements caused by long-term use of the Parkinson’s drug levodopa... -
Target Validation, 2012Cannabinoid CB2 Receptors as a New Target for the Treatment of Disease Progression in Parkinson's Disease: Studies in LRRK2-Transgenic Pre-clinical Models
Objective/Rationale:
Cannabinoids provide neuroprotection in neurodegenerative disorders through the activation of specific targets within the so-called endocannabinoid system. The case... -
Resource: Utilizing DATATOP Biospecimens, 2012Circulating MicroRNAs: a New Paradigm for Parkinson's Disease Biomarker Discovery
Objective/Rationale:
We aim to assess miRNA stability and evaluate the potential of previously identified PD-predictive circulating miRNAs as progression biomarkers for PD using MJFF... -
MJFF Research Grant, 2012Pre-clinical Safety Study of LRRK2 Inhibitors
Objective/Rationale:
LRRK2 is well recognized as a potential central nervous system target for the treatment of Parkinson’s disease (PD). For development as possible therapeutic drugs...
-
Resource: Utilizing DATATOP Biospecimens, 2012Small-molecule PD Biomarkers: a Metabolomic Analysis
Objective/Rationale:
Based on our earlier findings that yielded several promising biomarkers, this metabolomic study of small-molecule biochemicals will investigate specimens from... -
Dyskinesia LEAPS, 2012Xenon Inhalation to Reduce L-DOPA-Induced Dyskinesia
Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling L-DOPA-induced dyskinesia (LID) in the vast majority of patients. NMDA receptor...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.